Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig P Carden

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Humors of tumors: potential for interaction between cancer type and treating oncologist's personality?Craig P Carden, Ian R Judson
BJU International|August 16, 2008
A nomogram to predict the development of a nomogramCraig P Carden, Mark A Rosenthal
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
Small-cell lung cancer, getting smaller but still difficult to treatCraig P Carden, Mary E R O'Brien
European Journal of Cancer (Oxford, England : 1990)|June 5, 2007
Information about cancer clinical trials: an analysis of Internet resourcesCraig P Carden, Michael Jefford, Mark A Rosenthal
Current Opinion in Oncology|May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersCraig P Carden, Timothy A Yap, Stan B Kaye
Nature Reviews. Cancer|February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancerTimothy A Yap, Craig P Carden, Stan B Kaye
Molecular Cancer Therapeutics|August 13, 2009
Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptorCraig P Carden, L Rhoda Molife, Johann S de Bono
Neuro-Oncology|June 10, 2008
What is the risk of intracranial bleeding during anti-VEGF therapy?Craig P Carden, James M G Larkin, Mark A Rosenthal
The Lancet. Oncology|December 17, 2008
Eligibility of patients with brain metastases for phase I trials: time for a rethink?Craig P Carden, Roshan Agarwal, Frank Saran, et al.
Current Opinion in Pharmacology|July 16, 2008
Targeting CYP17: established and novel approaches in prostate cancerTimothy A Yap, Craig P Carden, Gerhardt Attard, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Humors of tumors: potential for interaction between cancer type and treating oncologist's personality?Craig P Carden, Ian R Judson
BJU International|August 16, 2008
A nomogram to predict the development of a nomogramCraig P Carden, Mark A Rosenthal
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
Small-cell lung cancer, getting smaller but still difficult to treatCraig P Carden, Mary E R O'Brien
European Journal of Cancer (Oxford, England : 1990)|June 5, 2007
Information about cancer clinical trials: an analysis of Internet resourcesCraig P Carden, Michael Jefford, Mark A Rosenthal
Current Opinion in Oncology|May 21, 2010
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersCraig P Carden, Timothy A Yap, Stan B Kaye
Nature Reviews. Cancer|February 25, 2009
Beyond chemotherapy: targeted therapies in ovarian cancerTimothy A Yap, Craig P Carden, Stan B Kaye
Molecular Cancer Therapeutics|August 13, 2009
Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptorCraig P Carden, L Rhoda Molife, Johann S de Bono
Neuro-Oncology|June 10, 2008
What is the risk of intracranial bleeding during anti-VEGF therapy?Craig P Carden, James M G Larkin, Mark A Rosenthal
The Lancet. Oncology|December 17, 2008
Eligibility of patients with brain metastases for phase I trials: time for a rethink?Craig P Carden, Roshan Agarwal, Frank Saran, et al.
Current Opinion in Pharmacology|July 16, 2008
Targeting CYP17: established and novel approaches in prostate cancerTimothy A Yap, Craig P Carden, Gerhardt Attard, et al.
Pageof 2